Patents Examined by Kimberly Breen
-
Patent number: 12644096Abstract: The present invention includes a method to increase romidepsin concentration in a bacteria fermentation media. Romidepsin concentration in a fermentation is increased by adding, for example, copper sulfate. The end resulting romidepsin concentration is increased by at least about two fold as compare to fermentation without copper sulfate.Type: GrantFiled: October 29, 2019Date of Patent: June 2, 2026Assignee: PRO FARM GROUP, INC.Inventors: Gian Oddone, Jacob Blodgett, Raul Reveles
-
Patent number: 12577292Abstract: A fusion nanoprotein is provided wherein TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment and exhibits enhanced cancer targeting using a cancer-targeting peptide. The fusion protein effectively targets cancer cells when injected into a blood vessel, leading to TRAIL-induced cancer cell death. This fusion nanoprotein addresses key challenges of TRAIL proteins by improving their stability and reducing off-target effects through stable delivery of TRAIL trimers specifically to cancer tissues. The enhanced stability and targeted delivery properties make this fusion protein a promising candidate for development as an anticancer therapeutic agent.Type: GrantFiled: March 6, 2020Date of Patent: March 17, 2026Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Soyoun Kim, Jae Do Yoo, Byung-Heon Lee, In Seon Jeon, In-San Kim
-
Patent number: 12578329Abstract: A reagent kit comprising a first polypeptide including a part in any one of amino acid sequences (A) to (C), and a second polypeptide including a part in any one of amino acid sequences (A) to (C), which are consistent of different sequences from a sequence of the first polypeptide; (A) an amino acid sequence in SEQ ID NO: 1 with deletion of an amino acid sequence from position 1 to 69 and an amino acid sequence from position 204 to 221, (B) an amino acid sequence in SEQ ID NO: 1 with deletion of an amino acid sequence from position 1 to 69 and deletion or substitution of at least one of amino acid residues at positions 146 to 156, (C) the amino acid sequence (A) or (B) with further deletion of at least one of amino acid residues at positions 70 to 74.Type: GrantFiled: May 19, 2022Date of Patent: March 17, 2026Assignee: SHIMADZU CORPORATIONInventor: Yuki Ohmuro
-
Patent number: 12527323Abstract: The present invention relates to a fusion protein having a targeting sequence, exosporium protein, or exosporium protein fragment that targets the fusion protein to the exosporium of a recombinant Bacillus cereus family member and an enzyme having serine protease activity, wherein the enzyme having serine protease activity is from Bacillus firmus or is a variant of such enzyme. The present invention also provides a recombinant Bacillus cereus family member that expresses such fusion protein and exosporium fragments derived from such recombinant Bacillus cereus family member. Methods of using such recombinant Bacillus cereus family members or exosporium fragments derived therefrom for nematode control are also provided.Type: GrantFiled: September 5, 2023Date of Patent: January 20, 2026Assignee: Bayer CropScience LPInventors: Damian Curtis, Kevin Bugg
-
Patent number: 12433938Abstract: Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).Type: GrantFiled: December 9, 2020Date of Patent: October 7, 2025Assignee: Alexion Pharmaceuticals, Inc.Inventors: Walter C. Voegtli, Michael Baranello, Keith Bouchard
-
Patent number: 12129504Abstract: The disclosure discloses Oscillospiraceae sp. LBM10036 capable of utilizing multiple substrates and application thereof, and belongs to the fields of microbial technology and Baijiu brewing. The microorganism Oscillospiraceae sp. LBM10036 of the disclosure was preserved in the Guangdong Microbial Culture Collection Center on Sep. 21, 2020, with the preservation number GDMCC No. 61202. The Oscillospiraceae sp. LBM10036 of the disclosure has the capability to utilize diverse substrates and high product specificity, adapts to low pH, and can efficiently synthesize caproic acid under a pH of 5.0-5.5. The strain used in the disclosure can be used for strengthening microorganisms in pit mud, and improving the quality of degraded pit mud, to improve the quality of Strong aroma-type Baijiu, and also can be used for producing caproic acid from a variety of sugars and lactic acid by microbial fermentation.Type: GrantFiled: September 27, 2023Date of Patent: October 29, 2024Assignee: Jiangnan UniversityInventors: Yan Xu, Cong Ren, Huilin Wang
-
Patent number: 12116566Abstract: Disclosed herein are methods and compositions for implementing a photosynthetic protein secretion platform.Type: GrantFiled: February 7, 2022Date of Patent: October 15, 2024Assignee: Alliance for Sustainable Energy, LLCInventors: Michael T. Guarnieri, Lukas Royce Dahlin, Marcus Salvatore Bray
-
Patent number: 12103948Abstract: Provided is a separating agent with an improved dynamic binding capacity (DBC) to a target substance. The separating agent includes a carrier and a protein, wherein the protein is a given protein, and a surface of the carrier and added lysine residues in the protein are bound by chemical bonds.Type: GrantFiled: July 1, 2019Date of Patent: October 1, 2024Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATIONInventors: Yoichi Kumada, Hiromichi Okura, Seiichi Uchimura
-
Patent number: 11666647Abstract: An approach for modifying multiple types of bacteria to produce surface modifications that enhance the immunologic response when used as a vaccine. A series of plasmids (pYF, pYFC, pYFP, pSF, pSPF, and pSCF) may be used to transform bacteria which then produce surface-exposed ligands that bind to complement receptors on antigen presenting cells. When modified bacteria are used as a vaccine, the vaccine recipients produce significantly higher titers of specific antibodies and are better protected against challenges from the disease-causing bacteria.Type: GrantFiled: September 29, 2020Date of Patent: June 6, 2023Assignee: ALBANY MEDICAL COLLEGEInventors: Karsten Hazlett, Kristen M. Tummillo, Edmund J. Gosselin